CD19 and acute lymphoblastic leukemia: Blinatumomab have received FDA approval for treating relapsed/refractory B-ALL (BLINCYTO® injection for the treatment of adults and children with CD19+B-cell precursor ALLin first or second CR with MRD ≥0.1%, or RR CD19+B-cell precursor ALL).